The Swiss pharma group has agreed a $9 per share deal to acquire Poseida, valuing the company at around $1 billion, with another $500 million potentially payable to shareholders in a contingent value ...
The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Report Ocean. Request To ...
Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody Recent clinical data from CD19 and BCMA targeted therapies ...
Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody Recent clinical data from CD19 and BCMA targeted ...
The U.S. company Aditum Bio and Chinese company Leads Biolabs today announced that they have founded Oblenio Bio, a new ...
Recent clinical data from CD19 and BCMA targeted therapies have demonstrated compelling efficacy in difficult-to-treat autoimmune diseases. Despite these promising results, there is a continued ...
Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody OAKLAND, Calif. and NANJING, China, Nov. 7, 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback